L3VLUP
ProSign in

GSK · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GSKLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GSK
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterGSKLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 20221 holders, $19m33 holders, $42.7bn
Q3 202218 holders, $3.9bn31 holders, $43.4bn
Q4 202218 holders, $4.9bn31 holders, $46.6bn
Q1 202313 holders, $4.4bn33 holders, $44.3bn
Q2 202313 holders, $4.3bn37 holders, $59.6bn
Q3 202316 holders, $4.5bn44 holders, $67.6bn
Q4 202313 holders, $4.5bn45 holders, $73.6bn
Q1 202413 holders, $5.3bn41 holders, $95.3bn
Q2 202410 holders, $4.6bn43 holders, $110bn
Q3 202410 holders, $4.9bn45 holders, $107bn
Q4 202413 holders, $4.9bn46 holders, $93.9bn
Q1 202511 holders, $6.3bn42 holders, $98.4bn
Q2 202510 holders, $6.2bn43 holders, $93.2bn
Q3 202511 holders, $7.5bn39 holders, $86.7bn
Q4 202511 holders, $8.8bn41 holders, $123bn
Q1 20269 holders, $9.1bn39 holders, $106bn
Q2 202611 holders, $7.5bn44 holders, $132bn
GSK

GSK PLC

Holders
11
Reported value
$7.5bn
Buyers
6
Sellers
5

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GSK (1)

Renaissance Technologies LLC

Only LLY (29)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Brevan Howard Capital Management LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Eisler Capital Management Ltd, Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Two Sigma Investments LP, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →